Review



1d11 pan tgfβ neutralizing antibody  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Bio X Cell 1d11 pan tgfβ neutralizing antibody
    (A) Schematic illustration of the <t>1D11</t> administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of <t>TGFβ</t> target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.
    1d11 Pan Tgfβ Neutralizing Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 89 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/InVivoMAb+anti-mouse+human+rat+monkey+hamster+canine+bovine+TGF-%CE%B2/pmc10410753-643-14-20
    Average 95 stars, based on 89 article reviews
    1d11 pan tgfβ neutralizing antibody - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Elevated TGFβ signaling contributes to ocular anterior segment dysgenesis in Col4a1 mutant mice"

    Article Title: Elevated TGFβ signaling contributes to ocular anterior segment dysgenesis in Col4a1 mutant mice

    Journal: Matrix biology : journal of the International Society for Matrix Biology

    doi: 10.1016/j.matbio.2022.05.001

    (A) Schematic illustration of the 1D11 administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of TGFβ target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.
    Figure Legend Snippet: (A) Schematic illustration of the 1D11 administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of TGFβ target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.

    Techniques Used: Staining, Control, Expressing, Comparison

    Related Articles

    other:

    Article Title: A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands
    Article Snippet: The TGF-β pan-neutralizing antibody 1D11 was purchased from BioXCell (BioXCell, West Lebanon, NH).



    Similar Products

    95
    Bio X Cell 1d11 pan tgfβ neutralizing antibody
    (A) Schematic illustration of the <t>1D11</t> administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of <t>TGFβ</t> target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.
    1d11 Pan Tgfβ Neutralizing Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/InVivoMAb+anti-mouse+human+rat+monkey+hamster+canine+bovine+TGF-%CE%B2/pmc10410753-643-14-20
    Average 95 stars, based on 1 article reviews
    1d11 pan tgfβ neutralizing antibody - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    93
    Bio X Cell pan tgfb neutralizing antibody 1d11
    (A) Schematic illustration of the <t>1D11</t> administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of <t>TGFβ</t> target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.
    Pan Tgfb Neutralizing Antibody 1d11, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/InVivoPlus+anti-mouse+human+rat+monkey+hamster+canine+bovine+TGF-%CE%B2/pm35933071-214-18-22
    Average 93 stars, based on 1 article reviews
    pan tgfb neutralizing antibody 1d11 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bio X Cell pan tgfβ neutralizing antibody 1d11
    (A) Schematic illustration of the <t>1D11</t> administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of <t>TGFβ</t> target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.
    Pan Tgfβ Neutralizing Antibody 1d11, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/InVivoPlus+anti-mouse+human+rat+monkey+hamster+canine+bovine+TGF-%CE%B2/bio_rxiv__2022__07__10__499446-175-13-17
    Average 93 stars, based on 1 article reviews
    pan tgfβ neutralizing antibody 1d11 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Sanofi pan-tgf-β neutralizing antibody 1d11
    Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice
    Pan Tgf β Neutralizing Antibody 1d11, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/monoclonal+antibody+1d11/pmc07894383-178-20-26
    Average 90 stars, based on 1 article reviews
    pan-tgf-β neutralizing antibody 1d11 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genzyme neutralizing pan-tgf-β antibody 1d11
    Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice
    Neutralizing Pan Tgf β Antibody 1d11, supplied by Genzyme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/enzyme+linked+immunosorbent+assay/pmc05802812-724-4-7
    Average 90 stars, based on 1 article reviews
    neutralizing pan-tgf-β antibody 1d11 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genzyme pan-tgf-β neutralizing antibody clone 1d11
    Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice
    Pan Tgf β Neutralizing Antibody Clone 1d11, supplied by Genzyme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/enzyme+linked+immunosorbent+assay/pmc05394267-105-11-14
    Average 90 stars, based on 1 article reviews
    pan-tgf-β neutralizing antibody clone 1d11 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Bio X Cell tgf-β pan-neutralizing antibody 1d11
    Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice
    Tgf β Pan Neutralizing Antibody 1d11, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/anti+tgf+%CE%B2/pmc05349899-140-1-8
    Average 90 stars, based on 1 article reviews
    tgf-β pan-neutralizing antibody 1d11 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    95
    R&D Systems pan tgf β neutralizing igg 1 antibody 1d11
    Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice
    Pan Tgf β Neutralizing Igg 1 Antibody 1d11, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf-%CE%B2+pan-neutralizing+antibody+1d11/TGF-beta+1+Antibody/pmc03920204-116-16-21
    Average 95 stars, based on 1 article reviews
    pan tgf β neutralizing igg 1 antibody 1d11 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Schematic illustration of the 1D11 administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of TGFβ target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.

    Journal: Matrix biology : journal of the International Society for Matrix Biology

    Article Title: Elevated TGFβ signaling contributes to ocular anterior segment dysgenesis in Col4a1 mutant mice

    doi: 10.1016/j.matbio.2022.05.001

    Figure Lengend Snippet: (A) Schematic illustration of the 1D11 administration paradigm for histological analysis. (B) Representative images of H&E stained sections (left) showing whole eyes (top panels) and corneas (lower panels) from E18.5 mice and quantification graph (right) showing increased corneal stromal thickness in Col4a1+/G1344D mice treated with 1D11 compared to those that received the control IgG1 antibody. Scale bars = 200 μm (top) and 50 μm (bottom). n = 20 and 24 corneas from IgG1- and 1D11-treated Col4a1+/+ mice, and 24 and 30 corneas from IgG1- and 1D11-treated Col4a1+/G1344D mice, respectively. (C) Schematic illustration of the 1D11 administration paradigm for qPCR analyses. (D) qPCR analyses revealed that 1D11 treatment partially prevented the increased expression of TGFβ target genes in anterior segments from P0 Col4a1+/G1344D mice compared to their IgG1-treated counterparts. n = 5–6 samples per genotype. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, two-way ANOVA and Tukey’s multiple comparison test.

    Article Snippet: Timed-pregnant B6 females crossed with Col4a1 +/ G1344D males were injected intraperitoneally with the 1D11 pan-TGFβ neutralizing antibody (clone 1D11.16.8, BioXCell, West Lebanon, NH) or IgG1 isotype control antibody (clone MOPC-21, BioXCell) diluted in inVivoPure Dilution Buffer (pH 7.0, BioXCell) (20 mg/kg) every other day from E8.5 to E16.5 and animals were harvested at E18.5 or P0 for histological and molecular analyses, respectively.

    Techniques: Staining, Control, Expressing, Comparison

    Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice

    Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    Article Title: Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment

    doi: 10.1002/jbmr.2997

    Figure Lengend Snippet: Micro-CT Parameters of Midshaft Femoral Cortical Bone for WT, Crtap −/− , and Col1a2 +/p.G610C Mice

    Article Snippet: As described, ( 10 ) 8-week-old female Crtap −/− and Col1a2 +/p.G610C mice were treated for 8 weeks with the pan-TGF-β neutralizing antibody 1D11 (provided by Sanofi Genzyme, Cambridge, MA, USA); control female Crtap −/− , Col1a2 +/p.G610C , and WT mice were treated with a control antibody (13C4) of the same IgG1 isotype that does not inhibit TGF-β.

    Techniques: Micro-CT

    (A) The extrinsic mechanical parameters maximum load, stiffness, post-yield energy, and post-yield displacement of femurs from WT, OI control, and anti-TGF-β-treated (OI anti-TGF-β) mice are shown for the Crtap−/− and Col1a2+/p.G610C models. (B) The intrinsic mechanical parameters ultimate strength, elastic modulus, post-yield toughness, and post-yield strain of femurs of WT, OI control, and OI anti-TGF-β mice are shown for the Crtap−/− and Col1a2+/p.G610C models. *p < 0.05. The mechanical parameters of femurs of Crtap−/− mice are parts of the data set included in an earlier publication(10) and are reproduced here for ease in comparing to the data from the Col1a2+/p.G610C model.

    Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    Article Title: Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment

    doi: 10.1002/jbmr.2997

    Figure Lengend Snippet: (A) The extrinsic mechanical parameters maximum load, stiffness, post-yield energy, and post-yield displacement of femurs from WT, OI control, and anti-TGF-β-treated (OI anti-TGF-β) mice are shown for the Crtap−/− and Col1a2+/p.G610C models. (B) The intrinsic mechanical parameters ultimate strength, elastic modulus, post-yield toughness, and post-yield strain of femurs of WT, OI control, and OI anti-TGF-β mice are shown for the Crtap−/− and Col1a2+/p.G610C models. *p < 0.05. The mechanical parameters of femurs of Crtap−/− mice are parts of the data set included in an earlier publication(10) and are reproduced here for ease in comparing to the data from the Col1a2+/p.G610C model.

    Article Snippet: As described, ( 10 ) 8-week-old female Crtap −/− and Col1a2 +/p.G610C mice were treated for 8 weeks with the pan-TGF-β neutralizing antibody 1D11 (provided by Sanofi Genzyme, Cambridge, MA, USA); control female Crtap −/− , Col1a2 +/p.G610C , and WT mice were treated with a control antibody (13C4) of the same IgG1 isotype that does not inhibit TGF-β.

    Techniques:

    Bone compositional parameters mineral-to-collagen ratio, carbonate substitution, collagen content, and hydroxyapatite crystallinity determined by Raman spectroscopy of femurs are shown for WT, OI control, and OI anti-TGF-β mice for the Crtap−/− and Col1a2+/p.G610C models. *p < 0.05.

    Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    Article Title: Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment

    doi: 10.1002/jbmr.2997

    Figure Lengend Snippet: Bone compositional parameters mineral-to-collagen ratio, carbonate substitution, collagen content, and hydroxyapatite crystallinity determined by Raman spectroscopy of femurs are shown for WT, OI control, and OI anti-TGF-β mice for the Crtap−/− and Col1a2+/p.G610C models. *p < 0.05.

    Article Snippet: As described, ( 10 ) 8-week-old female Crtap −/− and Col1a2 +/p.G610C mice were treated for 8 weeks with the pan-TGF-β neutralizing antibody 1D11 (provided by Sanofi Genzyme, Cambridge, MA, USA); control female Crtap −/− , Col1a2 +/p.G610C , and WT mice were treated with a control antibody (13C4) of the same IgG1 isotype that does not inhibit TGF-β.

    Techniques: Raman Spectroscopy

    Pearson Correlation Coefficients Between the Mechanical Properties and the Raman Imaging Data for the Crtap −/− Model

    Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    Article Title: Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment

    doi: 10.1002/jbmr.2997

    Figure Lengend Snippet: Pearson Correlation Coefficients Between the Mechanical Properties and the Raman Imaging Data for the Crtap −/− Model

    Article Snippet: As described, ( 10 ) 8-week-old female Crtap −/− and Col1a2 +/p.G610C mice were treated for 8 weeks with the pan-TGF-β neutralizing antibody 1D11 (provided by Sanofi Genzyme, Cambridge, MA, USA); control female Crtap −/− , Col1a2 +/p.G610C , and WT mice were treated with a control antibody (13C4) of the same IgG1 isotype that does not inhibit TGF-β.

    Techniques: Imaging

    Pearson Correlation Coefficients Between the Mechanical Properties and the Raman Imaging Data for the Col1a2 +/p.G610C Model

    Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    Article Title: Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment

    doi: 10.1002/jbmr.2997

    Figure Lengend Snippet: Pearson Correlation Coefficients Between the Mechanical Properties and the Raman Imaging Data for the Col1a2 +/p.G610C Model

    Article Snippet: As described, ( 10 ) 8-week-old female Crtap −/− and Col1a2 +/p.G610C mice were treated for 8 weeks with the pan-TGF-β neutralizing antibody 1D11 (provided by Sanofi Genzyme, Cambridge, MA, USA); control female Crtap −/− , Col1a2 +/p.G610C , and WT mice were treated with a control antibody (13C4) of the same IgG1 isotype that does not inhibit TGF-β.

    Techniques: Imaging